On April 28, 2026 Kestrel Therapeutics Inc. ("Kestrel" or the "Company"), a clinical stage biotechnology company developing next-generation small-molecule inhibitors targeting mutant KRAS, reported that that the first patient has been dosed in its Phase 1 clinical trial evaluating KST-6051, its investigational, oral, small-molecule pan-KRAS inhibitor, in patients with advanced or metastatic solid tumors with KRAS mutations. In conjunction, the Company announced that it has entered into a strategic agreement with AbbVie, a leading global biopharmaceutical company. The deal is structured as a warrant agreement with an exclusive option for AbbVie to acquire Kestrel based on defined development milestones.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KST-6051 is an investigational pan-KRAS inhibitor designed to offer a differentiated mechanism of action. Its novel binding mode is designed to enable a durable target pathway suppression, which may confer a clinical efficacy advantage over other pathway inhibitors. KST-6051 is designed to bind directly to KRAS in both its active and inactive states, thereby providing broad coverage of oncogenic signaling while selectively sparing HRAS and NRAS. This selectivity profile may reduce the toxicity risks associated with non-selective pan-RAS inhibition.

"This strategic agreement represents a major validation of our lead pan-KRAS program," said Dr. Frank Haluska, Chief Executive Officer of Kestrel Therapeutics. "AbbVie’s commitment underscores the potential of our approach to address one of the most important targets in oncology. And dosing the first patient in our Phase 1 trial marks an important step forward in the clinical development of KST-6051. We believe KST-6051 has the potential to address significant unmet medical needs in patients with KRAS-driven cancers, and look forward to advancing this study and generating initial clinical data with AbbVie."

"KRAS mutations drive tumor growth and survival among many cancers. While earlier KRAS inhibitors targeted specific mutations, a new wave of pan-KRAS inhibitors are exploring the potential for broader patient impact," said Eleni Lagkadinou, M.D., Vice President, Oncology Early Development, AbbVie. "We’re looking forward to exploring how these advances can help complement our pipeline of antibody-drug conjugates and immunotherapies to accelerate innovation for patients."

The deal with AbbVie is structured as a warrant agreement with an exclusive option for AbbVie to acquire the Company. Under the terms of the agreement AbbVie will support funding of the KST-6051 program and based on the completion of development and regulatory milestones will have the exclusive option to acquire Kestrel. Including the upfront payment, future exercise payments and downstream development and regulatory milestones, the value of the deal could reach up to $1.45 billion.

About KST-6051

KST-6051 is a potential best-in-class, oral pan-KRAS inhibitor, developed for the treatment of KRAS-driven cancers. KST-6051 is a potent and selective inhibitor of KRAS with activity against KRAS in both its active (GTP-bound) and inactive (GDP-bound) states, while selectively sparing HRAS and NRAS. Preclinical data demonstrate robust on-target pathway modulation, anti-proliferative activity, and efficacy at well-tolerated doses in multiple human KRAS mutant tumor models. The clinical development program will ultimately address pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and other KRAS-driven malignancies.

About Phase 1 Trial KST-6051-101 (FALCON)

The Phase 1 study, KST-6051-101 (FALCON), is an open-label, multicenter, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of KST-6051 in patients with advanced solid tumors harboring KRAS mutations, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and other KRAS-driven malignancies

The trial will enroll patients with advanced metastatic solid tumors who have progressed following standard therapies. The study consists of a dose-escalation phase which will be followed by expansion cohorts in selected tumor types.

Primary objectives include evaluation of safety and tolerability, and determination of the recommended dose for expansion (RDE). Secondary and exploratory objectives include preliminary assessments of antitumor activity, pharmacokinetics, and pharmacodynamics.

Additional information about the trial is available at ClinicalTrials.gov [NCT07458347]

(Press release, Kestrel Therapeutics, APR 28, 2026, View Source [SID1234664877])

On April 28, 2026 Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, reported that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Orca-Q, Orca Bio’s second-generation investigational allogeneic T-cell immunotherapy for the treatment of high-risk hematologic malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The FDA’s RMAT designation for Orca-Q recognizes the significant unmet need for patients with serious hematologic malignancies and validates the promising clinical findings from our ongoing Phase 1 study," said Nate Fernhoff, Ph.D., co-founder and chief executive officer at Orca Bio. "As this is our second cell therapy candidate to receive RMAT status, we have experienced firsthand how this program can support accelerated development and enhanced communication with the FDA. With our newly expanded Phase 1 study continuing to enroll patients and additional data expected later this year, we remain focused on advancing our high-precision approach to deliver an important new treatment to patients with blood cancer."

The RMAT application included data from the ongoing Phase 1 clinical trial (NCT03802695) evaluating Orca-Q for the treatment of hematologic malignancies across six treatment cohorts, including in patients with haploidentical donors, and in patients receiving non-myeloablative or reduced intensity conditioning. Clinical findings demonstrated durability and encouraging outcomes across key metrics, including overall survival, acute and chronic graft versus host disease (GVHD) and non-relapse mortality. Enrollment is ongoing, with new data expected to be presented at upcoming scientific congresses. Additional details can be found on www.ClinicalTrials.gov.

RMAT designation is a specialized FDA program created to accelerate the development and review of promising new therapies, including cell therapies, intended to treat serious or life-threatening conditions. To qualify, a therapy must demonstrate preliminary clinical evidence suggesting the potential to address unmet medical needs. This designation provides important opportunities during the drug development process, including increased FDA guidance and eligibility for priority and rolling reviews, as well as accelerated approval pathways. By streamlining these regulatory milestones, the program aims to bring transformative innovations to patients more quickly.

About Orca-Q
Orca-Q is Orca Bio’s second-generation investigational allogeneic T-cell immunotherapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies, including in patients with haploidentical and mismatched donors. Orca-Q is a proprietary composition of stem cells combined with specific T-cell subsets derived from healthy donors and engineered by Orca Bio’s high-precision platform.

(Press release, Orca Bio, APR 28, 2026, View Source;utm_medium=rss&utm_campaign=orca-bio-announces-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-granted-to-orca-q-for-the-treatment-of-high-risk-hematologic-malignancies [SID1234664861])

On April 28, 2026 Juniper Biosciences reported a strategic licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development of JBS-003 (18F-fluoromisonidazole, or FMISO). This first-in-class hypoxia tracer in the U.S. is the cornerstone of a new precision oncology paradigm designed to spare patients from the devastating side effects of high-dose radiation therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Human Toll of "One-Size-Fits-All" Radiation

In the current standard of care for HPV-positive Oropharyngeal Carcinoma (OPC), patients are subjected to a "one-size-fits-all" aggressive radiation regimen regardless of their individual tumor biology. This maximum-dose approach often results in severe, permanent morbidity—including the risk of jawbone removal (osteoradionecrosis), significant weight loss requiring feeding tubes, and long-term quality-of-life impairment.

Redefining the Standard of Care: From 70 Gray to 30 Gray Radiation

JBS-003 utilizes precision molecular imaging to identify tumor hypoxia, a known marker of radioresistance. By mapping these oxygen-starved regions, clinicians can, for the first time, accurately risk-stratify patients. Research indicates that approximately 75-80% of these patients have non-hypoxic tumors and may safely undergo a 67% reduction in radiation, de-escalating from the standard 70 Gray (7 weeks) to 30 Gray (3 weeks) absorbed dose of ionizing radiation.

This transformation represents a significant opportunity for the healthcare system to improve clinical outcomes while reducing the high costs associated with managing long-term radiation toxicity and surgical interventions.

Expanding the Precision Radiopharmaceutical Platform

JBS-003 is a vital component of Juniper Biosciences’ expanding multi-indication precision platform. This partnership with MSK underscores Juniper’s commitment to building a high-value pipeline that addresses the most complex challenges in nuclear medicine.

"We are excited to announce our newest clinical pipeline asset and collaboration with MSK. Using F-MISO PET imaging, we can now visualize the specific hypoxic signatures of a tumor to maintain aggressive control where it’s needed, while safely reducing radiation doses for patients with well-oxygenated tissue. This effectively minimizes toxicity and preserves long-term quality of life. We aren’t just treating the cancer; we are preserving the patient’s future" said Alex Agnoletto, CEO.

"This collaboration is exciting because it combines our deeply validated clinical data with a partner positioned to efficiently translate it into a regulatory pathway toward FDA approval. Together, we can accelerate the impact of this work—moving from promising clinical evidence to a scalable solution that meaningfully improves patient outcomes," said Nancy Lee, MD, FASTRO, Vice Chair, Experimental Therapeutics, Department of Radiation Oncology; Service Chief, Head & Neck Radiation Oncology; and Service Chief, Proton Therapy, at MSK.

Unveiling at the MSK Innovation Summit

The strategic roadmap for JBS-003 will be officially unveiled by Alex Agnoletto during a featured presentation at the MSK Innovation with Lasting Impact Summit on May 11, 2026. This presentation will serve as a prelude to the upcoming clinical milestones as the program moves toward a target regulatory filing window in late 2029.

About the JBS-003 Phase 3 Clinical Trial (NCT06563479)

The ongoing Phase 3 trial is a randomized, double-blind study evaluating FMISO-selected de-escalated radiation therapy. Patients in the personalized arm receive a FMISO scan at week two; those with non-hypoxic scans are eligible for a reduced 30 Gray radiation dose, while those with positive scans continue with the standard 70 Gray regimen. The trial is expected to reach primary completion in early 2028.

(Press release, Juniper Biosciences, APR 28, 2026, View Source [SID1234664878])

On April 28, 2026 Novartis reported Condensed Interim Financial Report.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Novartis, APR 28, 2026, View Source [SID1234665199])

On April 28, 2026 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, reported that new preclinical data from its PBGENE-DMD program have been accepted for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2026 Annual Meeting, taking place May 11-15, 2026, in Boston, Massachusetts. The accepted abstract highlights new data demonstrating compelling efficacy observed in early-juvenile mice supporting the potential benefit of earlier intervention with PBGENE-DMD in younger patient populations. These data build on previously shared updates showing treatment with PBGENE-DMD leads to durable functional improvement in a humanized Duchenne muscular dystrophy (DMD) mouse model.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation:

Abstract title: PBGENE-DMD gene editing drives safe, efficacious, and durable functional improvement in a humanized Duchenne muscular dystrophy mouse model

Session: Emerging molecular therapeutic strategies for muscular dystrophies
Presenter: Adam Michler Ph.D., DMD Research Lead
Presentation Type: Oral Presentation
Presentation Time: May 14, 2026 at 8:45 a.m. ET

About PBGENE-DMD, A Muscle-Targeted Excision Program

PBGENE-DMD is Precision’s development program for the treatment of Duchenne Muscular Dystrophy (DMD), a devastating genetic disease caused by mutations in the dystrophin gene that prevents production of the dystrophin protein, which is essential for maintaining muscle structural integrity and function. DMD affects approximately 15,000 patients in the U.S. alone, and there are currently no approved therapies capable of driving significant, durable functional improvements over time.

PBGENE-DMD is designed to durably improve function for approximately 60% of patients with DMD by employing two complementary ARCUS nucleases, delivered using a single AAV, to excise exons 45-55 of the dystrophin gene, restoring expression of a near full-length dystrophin protein. This protein more closely resembles normal dystrophin than synthetic, truncated microdystrophin approaches, which offer minimal functional benefit. Precision’s Phase 1/2 FUNCTION-DMD study is expected to enroll ambulatory DMD patients with mutations between exons 45 and 55, which impact approximately 60% of boys with DMD. The clinical trial will employ an appropriate immune modulation regimen and safety monitoring program to treat patients at world class specialized DMD clinical sites.

PBGENE-DMD was granted Orphan Drug Designation by the FDA in July 2025. The PBGENE-DMD program is eligible for a Priority Review Voucher (PRV) via the Rare Pediatric Disease Priority Review Voucher (PRV) program, which was signed into law on February 3, 2026, as part of the Consolidated Appropriations Act of 2026. PBGENE-DMD received Fast Track designation from the FDA in February 2026.

Further details on the trial can be found on Precision’s website and clinicaltrials.gov identifier NCT07429240.

(Press release, Precision Biosciences, APR 28, 2026, View Source [SID1234664862])